Lyell Immunopharma (LYEL) FCF Margin (2020 - 2026)
Lyell Immunopharma (LYEL) posted FCF Margin of 1929950.0% for Q1 2026, down 250.57% sequentially from 550516.67% in Q4 2025, and down 114576429.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Lyell Immunopharma (LYEL) FCF Margin (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported FCF Margin for 7 years, with the latest figure at 1929950.0% in Q1 2026.
- Quarterly FCF Margin fell 114576429.0% year-over-year to 1929950.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 433903.23% (down 16408015.0% YoY) and the FY2025 annual result came in at 418900.0%, down 15244426.0% from the prior year.
- FCF Margin declined to 1929950.0% in Q1 2026 per LYEL's latest filing, from 550516.67% in the prior quarter.
- Over five years, FCF Margin peaked at 45.26% in Q4 2022 and troughed at 1929950.0% in Q1 2026.
- A 5-year average of 505406.79% and a median of 293184.62% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 177391633 bps in 2022, then surged 163391200 bps in 2023.
- Over 5 years, FCF Margin stood at 45.26% in 2022, then plunged by 736192 bps to 333223.08% in 2023, then slipped by 28 bps to 426963.64% in 2024, then retreated by 29 bps to 550516.67% in 2025, then sank by 251 bps to 1929950.0% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 1929950.0%, 550516.67%, and 187753.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Lyell Immunopharma | 335.97 Mn | 335.97 Mn | - | -851,875.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -851,875.00% |
| Mar 31, 2026 | -1,935,100.00% |
| Dec 31, 2025 | -542,583.33% |
| Sep 30, 2025 | -190,926.67% |
| Jun 30, 2025 | -432,825.00% |
| Mar 31, 2025 | -785,485.71% |
| Dec 31, 2024 | -429,872.73% |
| Sep 30, 2024 | -103,238.24% |
| Jun 30, 2024 | -294,115.38% |
| Mar 31, 2024 | -1,407,866.67% |
| Dec 31, 2023 | -312,769.23% |
| Sep 30, 2023 | -151,524.00% |
| Jun 30, 2023 | -148,496.30% |
| Mar 31, 2023 | -73,453.85% |
| Dec 31, 2022 | -92.69% |
| Sep 30, 2022 | -1,329,800.00% |
| Jun 30, 2022 | -144.10% |
| Mar 31, 2022 | -10,413.20% |
| Dec 31, 2021 | -1,540.79% |
| Sep 30, 2021 | -1,346.32% |